Genetic aspects of Alzheimer's disease

Acta Neurobiologiae Experimentalis

Volumn 64, Issue 1, 2004, Pages 19-31

  Zekanowski, Cezary ^a,b   Religa, Dorota ^b,c   Graff, Caroline ^c   Filipek, Sławomir ^a   Kuźnicki, Jacek ^a,d  

^a INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^b MOSSAKOWSKI MEDICAL RESEARCH CENTRE   (Poland)

^c KAROLINSKA INSTITUTE   (Sweden)

^d NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

Author keywords

Alzheimer's disease (AD); Amyloid peptide; ApoE; APP; Genetics; Presenilin

Indexed keywords

AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E4; PRESENILIN 1; PRESENILIN 2;

ALLELE; ALZHEIMER DISEASE; CHROMOSOME 1; CHROMOSOME 14; CHROMOSOME 19; CHROMOSOME 21; DEGENERATIVE DISEASE; FAMILIAL DISEASE; GENE LOCATION; GENE MUTATION; HEREDITY; HUMAN; PATHOGENESIS; REVIEW; RISK FACTOR;

ALZHEIMER DISEASE; ARTHROGRYPOSIS; HUMANS; MEMBRANE PROTEINS; PRESENILIN-1; PRESENILIN-2;

EID: 1842607579     PISSN: 00651400     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (97)

1. Allinson TM, Parkin ET, Turner AJ, Hooper NM (2003) AD-AMs family members as amyloid precursor protein alpha-secretases. J Neurosci Res 74: 342-352.
2. Amtul Z, Lewis PA, Piper S, Crook R, Baker M, Findlay K, Singleton A, Hogg M, Younkin L, Younkin SG, Hardy J, Hutton M, Boeve BF, Tang-Wai D, Golde TE (2002) A presenilin 1 mutation associated with familial frontotemporal dementia inhibits gamma-secretase cleavage of APP and notch. Neurobiol Dis 9: 269-273.
3. Ancolio K, Dumanchin C, Barelli H, Warter JM, Brice A, Campion D, Frebourg T, Checler F (1999) Unusual phenotypic alteration of beta amyloid precursor protein (betaAPP) maturation by a new Val-715 → Met betaAPP-770 mutation responsible for probable early-onset Alzheimer's disease. Proc Natl Acad Sci U S A 96: 4119-4124.
4. Athan ES, Lee JH, Arriaga A, Mayeux RP, Tycko B (2002) Polymorphisms in the promoter of the human APP gene: functional evaluation and allele frequencies in Alzheimer disease. Arch Neurol 59: 1793-1799.
5. Badano JL, Katsanis N (2002) Beyond mendel: an evolving view of human genetic disease transmission. Nature Rev Genet 3: 779-789.
6. Baskin A (1998) The neurobiology of apolipoproteins and their recptors in CNS and Alzheimer's disease. Brain Res Brain Res Rev 27: 119-142.
7. Bergman A, Religa D, Karlstrom H, Laudon H, Winblad B, Lannfelt L, Lundkvist J, Naslund J (2003) APP intracellular domain formation and unaltered signaling in the presence of familial Alzheimer's disease mutations. 1: Exp Cell Res 287: 1-9.
8. Binetti G, Signorini S, Squitti R, Alberici A, Benussi L, Cassetta E, Frisoni GB, Barbiero L, Feudatari E, Nicosia F, Testa C, Zanetti O, Gennarelli M, Perani D, Anchisi D, Ghidoni R, Rossini PM (2003) Atypical dementia associated with a novel presenilin-2 mutation. Ann Neurol 54: 832-836.
9. Blacker D, Bertram L, Saunders AJ, Moscarillo TJ, Albert MS, Wiener H, Perry RT, Collins JS, Harrell LE, Go RC, Mahoney A, Beaty T, Fallin MD, Avramopoulos D, Chase GA, Folstein MF, McInnis MG, Bassett SS, Doheny KJ, Pugh EW, Tanzi RE; NIMH Genetics Initiative Alzheimer's Disease Study Group (2003) Results of a high-resolution genome screen of 437 Alzheimer's disease families. Hum Mol Genet 12: 23-32.
10. Blennow K, Vanmechelen E (1998) Combination of the different biological markers for increasing specificity of in vivo Alzheimer's testing. J Neural Transm Suppl 53: 223-235.
11. Braak H, Braak E (1991) Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1: 213-216.
12. Breteler MM, Claus JJ, Van Dujin CM, Launer LJ, Hofman A (1992) Epidemiology of Alzheimer's disease. Epidemiol Rev 14: 59-82.
13. Brzyska M, Elbaum D (2003) Dysregulation of calcium in Alzheimer's disease. Acta Neurobiol Exp (Wars) 63: 171-183.
14. Burns MP, Noble WJ, Olm V, Gaynor K, Casey E, LaFrancois J, Wang L, Duff K (2003) Co-localization of cholesterol, apolipoprotein E and fibrillar Abeta in amyloid plaques. Brain Res Mol Brain Res 110: 119-125.
15. Cai D, Leem JY, Greenfield JP, Wang P, Kim BS, Wang R, Lopes KO, Kim SH, Zheng H, Greengard P, Sisodia SS, Thinakaran G, Xu H (2003) Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem 278: 3446-3454.
16. Campion D, Dumanchin C, Hannequin D, Dubois B, Belliard S, Puel M, Thomas-Anterion C, Michon A, Martin C, Charbonnier F, Raux G, Camuzat A, Penet C, Mesnage V, Martinez M, Clerget-Darpoux F, Brice A, Frebourg T (1999) Early-onset autosomal dominant Alzheimer disease: prevalence, genetic heterogeneity, and mutation spectrum. Am J Hum Genet 65: 664-670.
17. Cedazo-Minguez A, Cowburn RF (2001) Apolipoprotein E: a major piece in the Alzheimer's disease puzzle. J Cell Med Mol 5: 254-266.
18. Chapman J, Korczyn AD, Karussis DM, Michaelson DM (2001) The effects of APOE genotype on age at onset and progression of neurodegenerative diseases. Neurology 57: 1482-1485.
19. Chen Q, Schubert D (2002) Presenilin-interacting proteins. Expert Rev Mol Med 22: 1-18.
20. Christen Y (2003) Proteins and mutations: a new vision (molecular) of neurodegenerative diseases (in French). J Soc Biol 196: 85-94.
21. Combarros O, Alvarez-Arcaya A, Sanchez-Guerra M, Infante J, Berciano J (2002) Candidate gene association studies in sporadic Alzheimer's disease. Dement Geriatr Cogn Disord 14: 41-54.
22. Cotton RGH, Scriver CR (1998) Proof of a "disease causing" mutation. Hum Mutat 12: 1-3.
23. Croes EA, Dermaut B, van Der Cammen TJ, van Broeckhoven C, van Duijn CM (2000). Genetic testing should not be advocated as a diagnostic tool in familial forms of dementia. Am J Hum Gene. 67: 1033-1035.
24. Crook R, Verkkoniemi A, Perez-Tur J, Mehta N, Baker M, Houlden H, Farrer M, Hutton M, Lincoln S, Hardy J, Gwinn K, Somer M, Paetau A, Kalimo H, Ylikoski R, Poyhonen M, Kucera S, Haltia M (1998) A variant of Alzheimer's disease with spastic paraparesis and unusual plaques due to deletion of exon 9 of presenilin 1. Nat Med 4: 452-455.
25. De Ferrari GV, Chacon MA, Barria MI, arrido JL, Godoy JA, Olivares G, Reyes AE, Alvarez A, Bronfman M, Inestrosa NC (2003) Activation of Wnt signalling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol Psychiatry 8: 195-208.
26. Eckman CB, Mehta ND, Crook R, Perez-tur J, Prihar G, Pfeiffer E, Graff-Radford N, Hinder P, Yager D, Zenk B, Refolo LM, Prada CM, Younkin SG, Hutton M, Hardy J (1997) A new pathogenic mutation in the APP gene (1716V) increases the relative proportion of A beta 42(43). Hum Mol Genet 6: 2087-2089.
27. Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160: 113-123.
28. Ellis J, Pinheiro TJT (2002) Danger - misfolding proteins. Nature 416: 483-484.
29. Emahazion T, Feuk L, Jobs M, Sawyer SL, Fredman D, St Clair D, Prince JA, Brookes AJ (2001) SNP association studies in Alzheimer's disease highlight problems for complex disease analysis. Trends Genet 17: 407-413.
30. Esler WP, Marshall JR, Stimson ER, Ghilardi JR, Vinters HV, Mantyh PW, Maggio JE (2002) Apolipoprotein E affects amyloid formation but not amyloid growth in vitro: mechanistic implications for apoE4 enhanced amyloid burden and risk for Alzheimer's disease. Amyloid 9: 1-12.
31. Ezquerra M, Lleo A, Castellvi M, Queralt R, Santacruz P, Pastor P, Molinuevo JL, Blesa R, Oliva R (2003) A novel mutation in the PSEN2 gene (T430M) associated with variable expression in a family with early-onset Alzheimer disease. Arch Neurol 60: 1149-1151.
32. Farmery MR, Tjernberg LO, Pursglove SE, Bergman A, Winblad B, Naslund J (2003) Partial purification and characterization of gamma-secretase from post-mortem human brain. J Biol Chem 278: 24277-24284.
33. Fath T, Eidenmuller J, Brandt R (2002) Tau-mediated cytotoxicity in a pseudophosphorylation model of Alzheimer's disease. J Neurosci 22: 9733-9741.
34. Finckh U (2003) The future of genetic association studies in Alzheimer's disease. J Neur Transm 110: 253-266.
35. Fortini ME (2002) Gamma-secretase-mediated proteolysis in cell-surface-receptor signalling. Nat Rev Mol Cell Biol 3: 673-684.
36. Gibson Wood W, Eckert GP, Igbavboa U, Muller WE (2003) Amyloid beta-protein interactions with membranes and cholesterol: causes or casualties of Alzheimer's disease. Biochim Biophys Acta 1610: 281-290.
37. Gomez-Ramos A, Smith MA, Perry G, Avila J (2004) Tau phosphorylation and assembly. Acta Neurobiol Exp (Wars) 64: 33-39.
38. Grabowski TJ, Cho HS, Vonsattel JP, Rebeck GW, Greenberg SM (2002) Novel amyloid precursor protein mutation in an Iowa family with dementia and severe cerebral amyloid angiopathy. Ann Neurol 49: 697-705.
39. Haass C, Steiner H (2001) Protofibrils, the unifying toxic molecules of neurodegenerative disorders? Nature Neurosci 4: 859-860.
40. Haass C, Hung AY, Selkoe DJ, Teplow DB (1994) Mutations associated with a locus for familial Alzheimer's disease result in alternative processing of amyloid beta-protein precursor. J Biol Chem 269: 17741-17748.
41. Hartley DM, Walsh DM, Ye CP, Diehl T, Vasquez S, Vassilev PM, Teplow DB, Selkoe DJ (1999) Protofibrillar intermediates of amyloid beta-protein induce acute electrophysiological changes and progressive neurotoxicity in cortical neurons. J Neurosci 19: 8876-8884.
42. Hedera P (2001) Ethical principles and pitfalls of genetic testing for dementia. J Geriatr Psych Neurol 14: 213-221.
43. Herreman A, Hartmann D, Annaert W, Saftig P, Craessaerts K, Serneels L, Umans L, Schrijvers V, Checler F, Vanderstichele H, Baekelandt V, Dressel R, Cupers P, Huylebroeck D, Zwijsen A, Van Leuven F, De Strooper B (1999) Presenilin 2 deficiency causes a mild pulmonary phenotype and no changes in amyloid precursor protein processing but enhances the embryonic lethal phenotype of presenilin 1 deficiency. Proc Natl Acad Sci U S A 96: 11872-11877.
44. Hong CS, Caromile L, Nomata Y, Mori H, Bredesen DE, Koo EH (1999) Contrasting role of presenilin-1 and presenilin-2 in neuronal differentiation in vitro. J Neurosci 19: 637-643.
45. Jarret JT, Landsbury PT Jr (1993) Seeding "one dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73: 1055-1058.
46. Jellinger KA, Bancher C (1998) Neuropathology of Alzheimer's disease: a critical update. J Neural Transm Suppl 54: 77-95.
47. Juva K, Verkkoniemi A, Viramo P, Polvikoski T, Kainulainen K, Kontula K, Sulkava R (2000) APOE epsilon4 does not predict mortality, cognitive decline, or dementia in the oldest old. Neurology 54: 412-415.
48. Kehoe P, Wavrant-De Vrieze F, Crook R, Wu WS, Holmans P, Fenton I, Spurlock G, Norton N, Williams H, Williams N, Lovestone S, Perez-Tur J, Hutton M, Chartier-Harlin MC, Shears S, Roehl K, Booth J, Van Voorst W, Ramic D, Williams J, Goate A, Hardy J, Owen MJ (1999) A full genome scan for late onset Alzheimer's disease. Hum Mol Genet 8: 237-245.
49. Kimberly WT, Wolfe MS (2003) Identity and function of gamma-secretase. J Neurosci Res 74: 353-360.
50. Kirsch C, Eckert GP, Koudinov AR, Muller WE (2003) Brain cholesterol, statins and Alzheimer's Disease. Pharmacopsychiatry 36 (Suppl 2): S113-119.
51. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F (2001) Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha -secretase ADAM 10. Proc Natl Acad Sci U S A 98: 5815-5820.
52. Krichevsky AM, King KS, Donahue CP, Khrapko K, Kosik KS (2003) A microRNA array reveals extensive regulation of microRNAs during brain development. RNA 9: 1274-1281.
53. Lambert JC, Araria-Goumidi L, Myllykangas L, Ellis C, Wang JC, Bullido MJ, Harris JM, Artiga MJ, Hernandez D, Kwon JM, Frigard B, Petersen RC, Cumming AM, Pasquier F, Sastre I, Tienari PJ, Frank A, Sulkava R, Morris JC, St Clair D, Mann DM, Wavrant-DeVrieze F, Ezquerra-Trabalon M, Amouyel P, Hardy J, Haltia M, Valdivieso F, Goate AM, Perez-Tur J, Lendon CL, Chartier-Harlin MC (2002) Contribution of APOE promoter polymorphisms to Alzheimer's disease risk. Neurology 59: 59-66.
54. Le TV, Crook R, Hardy J, Dickson DW (2001) Cotton wool plaques in non-familial late-onset Alzheimer disease. J Neuropathol Exp Neurol 60: 1051-1061.
55. Ling Y, Morgan K, Kalsheker N (2003) Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int J Bioch Cell Biol 35: 1505-1535.
56. Marquez-Sterling NR, Lo AC, Sisodia SS, Koo EH (1997) Trafficking of cell-surface beta-amyloid precursor protein: evidence that a sorting intermediate participates in synaptic vesicle recycling. J Neurosci 17: 140-151.
57. Mattick JS (2003) Noncoding RNAs: a regulatory role? In: Encyclopedia of Human Genome (Ed. C. D. Macmillan). London, New York, Nature Publishing Group.
58. Mattson MP (2002) Oxidative stress, perturbed calcium homeostatis and immune disfunction in Alzheimer's disease. J Neurovirol 8: 539-550.
59. McGeer PL, McGeer EG (2001) Polymorphisms in inflammatory genes and the risk of Alzheimer disease. Arch Neurol 58: 1790-1792.
60. Meyer MR, Tschanz JT, Norton MC (1994) APOE4 genotype predicts when - not whether - one is predisposed to develope Alzheimer disease. Nat Genet 7: 180-184.
61. Moehlmann T, Winkler E, Xia X, Edbauner D, Murrrell J, Capell A, Kaether C, Zheng H, Ghetti B, Haass C, Steiner H (2002) Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A 99: 8025-8030.
62. Mullan M, Crawford F, Axelman K, Houlden H, Lilius L, Winblad B, Lannfelt L (1992) A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N-terminus of beta-amyloid. Nat Genet 1: 345-347.
63. Myers A, Holmans P, Marshall H, Kwon J, Meyer D, Ramic D, Shears S, Booth J, DeVrieze FW, Crook R, Hamshere M, Abraham R, Tunstall N, Rice F, Carty S, Lillystone S, Kehoe P, Rudrasingham V, Jones L, Lovestone S, Perez-Tur J, Williams J, Owen MJ, Hardy J, Goate AM (2000) Susceptibility locus for Alzheimer's disease on chromosome 10. Science 290: 2304-2305.
64. Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG, Naslund J, Lannfelt L (2001) The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation. Nat Neurosci 4: 887-893.
65. Nussbaum RL, Ellis CE (2003) Alzheimer's disease and Parkinson's disease. N Engl J Med 348: 1356-1356.
66. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39: 409-421.
67. Papassotiropoulos A, Streffer JR, Tsolaki M, Schmid S, Thal D, Nicosia F, Iakovidou V, Maddalena A, Lutjohann D, Ghebremedhin E, Hegi T, Pasch T, Traxler M, Bruhl A, Benussi L, Binetti G, Braak H, Nitsch RM, Hock C (2003) Increased brain beta-amyloid load, phosphorylated tau, and risk of Alzheimer disease associated with an intronic CYP46 polymorphism. Arch Neurol 60: 29-35.
68. Pastor P, Roe CM, Villegas A, Bedoya G, Chakraverty S, Garcia G, Tirado V, Norton J, Rios S, Martinez M, Kosik KS, Lopera F, Goate AM (2003) Apolipoprotein Eepsilon4 modifies Alzheimer's disease onset in an E280A PS1 kindred. Ann Neurol 54: 163-169.
69. Pericak-Vance MA, Grubber J, Bailey LR, Hedges D, West S, Santoro L, Kemmerer B, Hall JL, Saunders AM, Roses AD, Small GW, Scott WK, Conneally PM, Vance JM, Haines JL (2000) Identification of novel genes in late-onset Alzheimer's disease. Exp Gerontol 35: 1343-1352.
70. Prince JA, Feuk L, Sawyer SL, Gottfries J, Ricksten A, Nagga K, Bogdanovic N, Blennow K, Brookes AJ (2001) Lack of replication of association findings in complex disease: an analysis of 15 polymorphisms in prior candidate genes for sporadic Alzheimer's disease. Eur J Hum Genet 9: 437-444.
71. Rademakers R, Cruts M, Van Broeckhoven C (2003) Genetics of early-onset Alzheimer dementia. Scientific-World Journal 3: 497-519.
72. Raiha I, Kaprio J, Koskenvuo M, Rajala T, Sourander L (1998) Environmental differences in twin pairs discordant for Alzheimer's disease. J Neurol Neurosurg Psychiatry 65: 785-787.
73. Religa D, Winblad B (2003) Therapeutic strategies for Alzheimer's disease based on new molecular mechanisms. Acta Neurobiol Exp (Wars) 63: 393-396.
74. Retz W, Thorne J, Durany N, Harsanyi A, Retz-Junginger P, Komhuber J, Riederer P, Rosler M (2001) Potential genetic markers of sporadic Alzheimer's dementia. Psychiatr Genet 11: 115-122.
75. Rocchi A, Pellegrini S, Siciliano G, Murri L (2003) Causative and susceptibility genes for Alzheimer's disease: a reviev. Brain Res Bull 61: 1-24.
76. Rogaeva E (2002) The solved and unsolved mystries of the genetics of early-onset Alzheimer's disease. Neuromolecular Med 2: 33-42.
77. Roher AE, Weiss N, Kokjohn TA, Kuo YM, Kalback W, Anthony J, Watson D, Luehrs DC, Sue L, Walker D, Emmerling M, Goux W, Beach T (2002) Increased A beta peptides and reduced cholesterol and myelin proteins characterize white matter degeneration in Alzheimer's disease. Biochemistry 41: 11080-11090.
78. Roks G, Van Harskamp F, De Koning I, Cruts M, De Jonghe C, Kumar-Singh S, Tibben A, Tanghe H, Niermeijer MF, Hofman A, Van Swieten JC, Van Broeckhoven C, Van Duijn CM (2000) Presentation of amyloidosis in carriers of the codon 692 mutation in the amyloid precursor protein gene (APP692). Brain 123: 2130-2140.
79. Seitz A, Kragol M, Aglow E, Showe L, Heber-Katz E (2003) Apolipoprotein E expression after spinal cord injury in the mouse. J Neurosci Res 71: 417-426.
80. Sleegers K, Van Duijn CM (2001) - Alzheimer's Disease: Genes, Pathogenesis and Risk Prediction. Community Genet 4: 197-203.
81. Suzuki N, Cheung TT, Cai XD, Odaka A, Otvos L Jr, Eckman C, Golde TE, Younkin SG (1994) An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. Science 264: 1336-1340.
82. Tandon A, Fraser P (2002) The presenilins. Genome Biol 3: 3014-3020.
83. Thal DR, Rub U, Orantes M, Braak H (2002) Phases of A beta-deposition in the human brain and its relevance for the development of AD. Neurology 58: 1791-1800.
84. Theuns J, Remacle J, Killick R, Corsmit E, Vennekens K, Huylebroeck D, Cruts M, Van Broeckhoven C (2003) Alzheimer-associated C allele of the promoter polymorphism -22C>T causes a critical neuron-specific decrease of presenilin 1 expression. Hum Mol Genet 12: 869-877.
85. Tol J, Slooter ACJ, Van Duijn CM (1999) Genetic factors in early- and late-onset Alzheimer's disease. In: Epidemiology of Alzheimer's disease: from gene to prevention (Eds. R. Mayeux and Y. Christen). Springer, Berlin, Heidelberg, New York, p. 33-39.
86. Trześniewska K, Brzyska M, Elbaum D (2004) Neurodegenerative aspects of protein aggregation. Acta Neurobiol Exp (Wars) 64: 41-52.
87. Van Gassen G, Van Broeckhoven C (2000) Molecular genetics of Alzheimer's disease: what have we learned? Acta Neurol Belg 100: 65-76.
88. Wada S, Morishima-Kawashima M, Qi Y, Misono H, Shimada Y, Ohno-Iwashita Y, Ihara Y (2003) Gamma-secretase activity is present in rafts but is not cholesterol-dependent. Biochemistry 42: 13977-13986.
89. Walsh DM, Klyubin I, Fadeeva JV, Cullen WK, Anwyl R, Wolfe MS, Rowan MJ, Selkoe DJ (2002) Naturally secreted oligomers of amyloid beta protein potently inhibit hippocampal long-term potentiation in vivo. Nature 416: 535-539.
90. Warwick Daw E, Payami H, Nemens EJ, Nochlin D, Bird TD, Schellenberg GD, Wijsman EM (2000) The number of trait loci in late-onset Alzheimer disease. Am J Hum Genet 66: 196-204.
91. Weiss KM (2000) Consulting the oracle: reverence, but criticism. Genet Epidem 19: 468-472.
92. Weiss KM, Terwilliger JD (2000) How many diseases does it take to map a gene with SNPs? Nature Genetics 26: 151-156.
93. Wolozin B (2001) A fluid connection: cholesterol and Abeta. Proc Natl Acad Sci U S A 98: 5371-5373.
94. Wolozin B (2003) Cyp46 (24S-cholesterol hydroxylase): a genetic risk factor for Alzheimer disease. Arch Neurol 60: 16-18.
95. Yu C, Kim SH, Ikeuchi T, Xu H, Gasparini L, Wang R, Sisodia SS (2001) Characterization of a presenilin-mediated amyloid precursor protein carboxyl-terminal fragment gamma. Evidence for distinct mechanisms involved in gamma -secretase processing of the APP and Notch1 transmembrane domains. J Biol Chem 276: 43756-43760.
96. Żekanowski C, Styczyńska M, Pepłońska B, Gabryelewicz T, Religa D, Ilkowski J, Kijanowska-Haładyna B, Kotapka-Minc S, Mikkelsen S, Pfeffer A, Barczak A, Łuczywek E, Wasiak B, Chodakowska-Żebrowska M, Gustaw M, Ła̧czkowski J, Sobów T, Kuźnicki J, Barcikowska M (2003) Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer disease in Poland. Exper Neurol 184: 991-996.
97. Żekanowski C, Pepłońska B, Styczyńska M, Religa D, Pfeffer A, Czyżewski, K, Gabryelewicz T, Szybińska A, Kijanowska-Haładyna B, Kotapka-Minc S, Łuczywek I, Barczak A, Wasiak B, Chodakowska-Żebrowska M, Przekop I, Kuźnicki J, Barcikowska M (2004) The E318G substitution in PSEN1 gene is not associated with AD in a large Polish cohort. Neurosci Lett 357: 167-170.